...
首页> 外文期刊>Archives of Pathology & Laboratory Medicine >High-Resolution Computed Tomography Screening for Lung Cancer: Unexpected Findings and New Controversies Regarding Adenocarcinogenesis
【24h】

High-Resolution Computed Tomography Screening for Lung Cancer: Unexpected Findings and New Controversies Regarding Adenocarcinogenesis

机译:肺癌的高分辨率计算机断层扫描筛查:腺癌发生的意外发现和新争议。

获取原文
获取原文并翻译 | 示例

摘要

CONTEXT: Recent advances in human imaging technologies reawakened interest in lung cancer screening. Although historic and current preliminary and noncontrolled studies have not shown a decrease in lung cancer mortality in screened populations, many explanations have been proffered while the lung cancer community awaits the results of several large controlled population studies. OBJECTIVE: To critically review the current model of adenocarcinoma development against the background of lung cancer screening results combined with observational pathologic and radiographic studies. DATA SOURCES: Published articles pertaining to lung cancer screening, lung adenocarcinoma pathology, and radiology accessible through PubMed form the basis for this review. CONCLUSIONS: The current adenocarcinogenesis model is probably valid for many but not all lung adenocarcinomas. Screening data combined with radiographic and pathologic studies suggest that not all lung adenocarcinomas are clinically aggressive, and it is uncertain whether all aggressive adenocarcinomas arise from identified precursors.
机译:背景:人类成像技术的最新进展重新唤起了人们对肺癌筛查的兴趣。尽管历史性的和当前的初步和非对照研究尚未显示出筛查人群的肺癌死亡率降低,但是在肺癌界等待数项大型对照人群研究的结果之时,已经做出了许多解释。目的:以肺癌筛查结果为背景,结合观察性病理和放射学研究,对当前腺癌发展模型进行严格审查。数据来源:与发表于PubMed的肺癌筛查,肺腺癌病理学和放射学有关的文章构成了本文的基础。结论:当前的腺癌发生模型可能对许多但不是全部的肺腺癌有效。结合放射线和病理学研究的筛查数据表明,并非所有肺腺癌在临床上都是侵袭性的,并且不确定是否所有侵袭性腺癌都源自已鉴定的前体。

著录项

  • 来源
    《Archives of Pathology & Laboratory Medicine》 |2010年第1期|p.41-48|共8页
  • 作者单位

    Lucian R. Chirieac, MD, Douglas B. Flieder, MDAccepted for publication February 12, 2009.From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Dr Chirieac), and the Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Dr Flieder).The authors have no relevant financial interest in the products or companies described in this article.Reprints: Douglas B. Flieder, MD, Department of Pathology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 (e-mail: Douglas.Flieder@fccc.edu).,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号